Literature DB >> 36266464

Commensal oral microbiota impacts ulcerative oral mucositis clinical course in allogeneic stem cell transplant recipients.

Julia S Bruno1, Vitor Heidrich1,2, Franciele H Knebel1, Vinícius Campos de Molla3, Claudia Joffily Parahyba4, Wanessa Miranda-Silva1, Paula F Asprino1, Luciana Tucunduva4, Vanderson Rocha4,5,6, Yana Novis4, Celso Arrais-Rodrigues3, Anamaria A Camargo1, Eduardo R Fregnani7.   

Abstract

Oral mucositis (OM) is a complex acute cytotoxicity of antineoplastic treatment that affects 40-85% of patients undergoing hematopoietic stem-cell transplantation. OM is associated with prolonged hospitalization, increased extensive pharmacotherapy, need for parenteral nutrition, and elevated treatment costs. As OM onset relates to the mucosal microenvironment status, with a particular role for microbiota-driven inflammation, we aimed to investigate whether the oral mucosa microbiota was associated with the clinical course of OM in patients undergoing allogeneic hematopoietic stem-cell transplantation. We collected oral mucosa samples from 30 patients and analyzed the oral mucosa microbiota by 16S rRNA sequencing. A total of 13 patients (43%) developed ulcerative OM. We observed that specific taxa were associated with oral mucositis grade and time to oral mucositis healing. Porphyromonas relative abundance at preconditioning was positively correlated with ulcerative OM grade (Spearman ρ = 0.61, P = 0.028) and higher Lactobacillus relative abundance at ulcerative OM onset was associated with shortened ulcerative OM duration (P = 0.032). Additionally, we generated a machine-learning-based bacterial signature that uses pre-treatment microbial profiles to predict whether a patient will develop OM during treatment. Our findings suggest that further research should focus on host-microbiome interactions to better prevent and treat OM.
© 2022. The Author(s).

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36266464      PMCID: PMC9584897          DOI: 10.1038/s41598-022-21775-3

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.996


  33 in total

1.  Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action.

Authors:  H R Wardill; S T Sonis; N M A Blijlevens; Y Z A Van Sebille; M A Ciorba; E A H Loeffen; K K F Cheng; P Bossi; L Porcello; D A Castillo; S Elad; J M Bowen
Journal:  Support Care Cancer       Date:  2020-06-26       Impact factor: 3.603

2.  A randomized, double-blind, placebo-controlled trial of probiotics to reduce the severity of oral mucositis induced by chemoradiotherapy for patients with nasopharyngeal carcinoma.

Authors:  Chunling Jiang; Huan Wang; Chaofei Xia; Qing Dong; En Chen; Yang Qiu; Yong Su; Honghui Xie; Lei Zeng; Jie Kuang; Fan Ao; Xiaochang Gong; Jingao Li; Tingtao Chen
Journal:  Cancer       Date:  2018-12-06       Impact factor: 6.860

3.  Lactobacillus brevis CD2 for Prevention of Oral Mucositis in Patients With Head and Neck Tumors: A Multicentric Randomized Study.

Authors:  Vitaliana DE Sanctis; Liliana Belgioia; Domenico Cante; Maria R LA Porta; Orietta Caspiani; Roberta Guarnaccia; Angela Argenone; Paolo Muto; Daniela Musio; Francesca DE Felice; Francesca Maurizi; Feisal Bunkhelia; Maria Grazia Ruo Redda; Alessia Reali; Maurizio Valeriani; Mattia F Osti; Daniela Alterio; Almalina Bacigalupo; Elvio G Russi
Journal:  Anticancer Res       Date:  2019-04       Impact factor: 2.480

Review 4.  The role of oral bacteria in inflammatory bowel disease.

Authors:  Emily Read; Michael A Curtis; Joana F Neves
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-08-16       Impact factor: 46.802

Review 5.  New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury.

Authors:  Marika Cinausero; Giuseppe Aprile; Paola Ermacora; Debora Basile; Maria G Vitale; Valentina Fanotto; Giuseppe Parisi; Lorenzo Calvetti; Stephen T Sonis
Journal:  Front Pharmacol       Date:  2017-06-08       Impact factor: 5.810

6.  Analysis of compositions of microbiomes with bias correction.

Authors:  Huang Lin; Shyamal Das Peddada
Journal:  Nat Commun       Date:  2020-07-14       Impact factor: 14.919

7.  Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors.

Authors:  Stephen S Dominy; Casey Lynch; Florian Ermini; Malgorzata Benedyk; Agata Marczyk; Andrei Konradi; Mai Nguyen; Ursula Haditsch; Debasish Raha; Christina Griffin; Leslie J Holsinger; Shirin Arastu-Kapur; Samer Kaba; Alexander Lee; Mark I Ryder; Barbara Potempa; Piotr Mydel; Annelie Hellvard; Karina Adamowicz; Hatice Hasturk; Glenn D Walker; Eric C Reynolds; Richard L M Faull; Maurice A Curtis; Mike Dragunow; Jan Potempa
Journal:  Sci Adv       Date:  2019-01-23       Impact factor: 14.136

8.  Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients.

Authors:  Alexa M G A Laheij; Judith E Raber-Durlacher; Renée G A Koppelmans; Marie-Charlotte D N J M Huysmans; Carin Potting; Stephanie J M van Leeuwen; Mette D Hazenberg; Michael T Brennan; Inger von Bültzingslöwen; Jan-Erik Johansson; Johannes J de Soet; Thijs M Haverman; Mark J Buijs; Bernd W Brandt; Frederik R Rozema; Nicole M A Blijlevens; Egija Zaura
Journal:  Sci Rep       Date:  2019-11-15       Impact factor: 4.379

9.  phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data.

Authors:  Paul J McMurdie; Susan Holmes
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

10.  Lasting Gammaproteobacteria profile changes characterized hematological cancer patients who developed oral mucositis following conditioning therapy.

Authors:  Jean-Luc C Mougeot; Micaela F Beckman; Craig B Stevens; Kathryn G Almon; Darla S Morton; Inger Von Bültzingslöwen; Michael T Brennan; Farah Bahrani Mougeot
Journal:  J Oral Microbiol       Date:  2020-05-13       Impact factor: 5.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.